Sec Form 3/A Filing - McDermott Charles Douglas @ Kala Pharmaceuticals, Inc. - 2017-07-19

FORM 3/A Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person McDermott Charles Douglas 2. Issuer Name and Ticker or Trading Symbol Kala Pharmaceuticals, Inc. [ KALA] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director X __ 10% Owner X __ Officer (give title below) _____ Other (specify below) President and Chief Bus. Off. (Last) (First) (Middle) C/O KALA PHARMACEUTICALS, INC., 100 BEAVER STREET, SUITE 201 3. Date of Earliest Transaction (MM/DD/YY) 07/19/2017 (Street) WALTHAM, MA02453 4. If Amendment, Date Original Filed (MM/DD/YY) 07/19/2017 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Stock Option (right to buy) $ 0.68 ( 1 )( 2 ) 06/14/2023 Common Stock 24,000 D Stock Option (right to buy) $ 2.3 ( 1 )( 3 ) 06/03/2018 Common Stock 62,056 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other McDermott Charles Douglas C/O KALA PHARMACEUTICALS, INC. 100 BEAVER STREET, SUITE 201 WALTHAM, MA02453 X President and Chief Bus. Off. Signatures /s/ Mary Reumuth, Attorney-in-Fact 07/21/2017 Signature of Reporting Person Date

Explanation of Responses:

( 1 )This form amends a Form 3 previously filed for the Reporting Person on July 19, 2017 to correct the description of the vesting schedule of stock options reported herein. ( 2 )This option was granted on June 14, 2013, and vests as to 100% of the shares underlying the option: (A) immediately prior to the closing of a change of control with aggregate consideration of greater than $300,000,000 or (B) following the Issuer's initial public offering with a resulting market capitalization of over $300,000,000 following the date of the expiration of market stand-off agreements executed in connection with the Issuer's initial public offering. This option will expire without vesting if neither condition occurs prior to June 3, 2018. ( 3 )This option was granted on October 2, 2014, and vests as follows: either (A) upon a change of control with aggregate consideration (i) in excess of $400 million, with respect to 100% of the shares underlying the option, (ii) from $300 million to $400 million, with respect to 66.667% of the shares underlying the option or (iii) from $250 million to $300 million, with respect to 33.333% of the shares underlying the option or (B) following the Issuer's initial public offering with a resulting market capitalization following the expiration of market stand-off agreements executed in connection with such offering (i) in excess of $400 million, with respect to 100% of the shares underlying the option, (ii) from $300 million to $400 million, with respect to 66.667% of the shares underlying the option or (iii) from $250 million to $300 million, with respect to 33.333% of the shares underlying the option. This option will expire without vesting if neither condition occurs before June 3, 2018.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.